Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated DiseasesNew Program is a ...

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...

FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...

Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

In terms of [Monjuvi] alone, [Monjuvi] is what we call an anti-CD19 monoclonal antibody. Essentially this drug targets CD19, which is a signal that is found on the surface of many of the cancer cells ...

The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide ...